Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time

Thursday, October 19, 2017

Source: Regeneron

TARRYTOWN, N.Y., Oct. 19, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Science magazine has once again ranked the company as the world's number one employer in its annual survey of the biotech and pharmaceutical industry. Regeneron has been ranked first for five of the past seven years, with second place rankings in 2015 and 2011, making the company the most highly ranked over the past decade.

"Our continued placement atop the Science Top Employers list is a reflection of our passionate colleagues who dedicate themselves each day to ground-breaking science that leads to life-changing medicines," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. "Maintaining our culture of innovation and collaboration has been a key priority as we continue to grow beyond 6,000 people, explore new areas of research and help more patients." 

The Science and Science Careers' 2017 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the best employers in these industries, as well as their driving characteristics. Survey respondents rated Regeneron highly based on 23 characteristics, including financial strength, easy adaptation to change and a research-driven environment. Employees rated Regeneron highest when it came to having a clear vision for the future, being socially responsible and treating colleagues with respect. 

"Regeneron is proud to once again be recognized as the world's number one employer in our industry," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "We also strive to be the best at bringing important new medicines to patients with unmet medical needs. That means having the best science, people and ethical standards, and creating an environment that rewards innovation and enables people to do their very best work."

According to Science, the 2017 global survey results were based on nearly 7,000 responses from North America (65 percent), Europe (25 percent) and the Asia/Pacific Rim (7 percent).

For the complete feature including individual company rankings, please visit 
About Regeneron  Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases. 

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite ® technologies, including VelocImmune® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit or follow @Regeneron on Twitter. 
Regeneron Media Relations Alexandra Bowie Tel: +1 (914) 847-3407

View original content:

SOURCE Regeneron Pharmaceuticals, Inc.
News Provided by Acquire Media

View All News »